Paul Detjen, MD
Allergy & Immunology · Kenilworth, ILNPI 1396739298
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,551 of the $14,367 with a category attached, or 66.5%. 28 manufacturers reported payments, led by Aimmune Therapeutics, Inc. at 32.7% of the total. Reporting peaked in 2021 at $5,695 and has fallen 69.0% since, to $1,763 in 2025.
Across 462 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$5K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Sanofi$969
- Genentech USA, Inc.$619
- plus $3K from 22 others
What the payments were for
- Consulting fees$3,45024%
- Travel & lodging$1,2048%
- Food & beverage$9,55166%
- Education$1631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 8 | $4,697 |
| AstraZeneca | 129 | $2,667 |
| Regeneron Healthcare Solutions, Inc. | 52 | $1,296 |
| GSK | 52 | $1,010 |
| Sanofi | 40 | $969 |
| Genentech USA, Inc. | 29 | $619 |
| Kaleo, Inc. | 30 | $551 |
| Novartis | 22 | $345 |
| Blueprint Medicines Corporation | 6 | $217 |
| Pharming Healthcare, Inc. | 8 | $196 |
| Teva Pharmaceuticals USA, Inc. | 9 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $175 |
| Pfizer | 8 | $171 |
| Optinose US, Inc. | 9 | $154 |
| Hikma Pharmaceuticals USA | 7 | $140 |
| Biocryst US Sales Co., LLC | 5 | $113 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| Covis Pharma GmbH | 5 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Amgen | 5 | $95 |
| Alk-abello, Inc | 5 | $94 |
| Phadia US Inc. | 5 | $90 |
| Boehringer Ingelheim | 4 | $79 |
| AbbVie | 3 | $69 |
| Circassia Inc. | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Cycle Pharmaceuticals Inc | 1 | $31 |
| Merck | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PALFORZIA$326
How this compares
$14,367 in reported general payments places this provider in the 80th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 30 | $130,470 |
| Dupixent SyringeDupilumab | 22 | $84,026 |
| TezspireTezepelumab-Ekko | 11 | $50,095 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $17,706 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,389 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $8,161 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,848 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,610 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $6,535 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $6,469 |
| Advair DiskusFluticasone Propion/Salmeterol | 15 | $6,125 |
| DuleraMometasone/Formoterol | 13 | $5,673 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,810 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $4,317 |
| Azelastine Hcl | 74 | $3,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $2,667 | $54,90422 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,010 | $39,94371 claims |
| MerckDulera | $20 | $5,67313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Kenilworth
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.